The StartupMDVisit Website →
← Back to blog

AI Bias in Healthcare Models: Causes, Examples and Fixes

October 28, 2026
AI Bias in Healthcare Models: Causes, Examples and Fixes

AI bias in healthcare models is a systematic gap in how a model performs for different patient groups. It usually starts in the data, grows through design choices, and shows up as missed diagnoses, wrong risk scores or unequal recommendations. You can find it, measure it and reduce it. But only if someone owns the job before launch and after.

I see this question from both sides: as a physician who has treated patients, and as an advisor to healthcare SaaS teams building and selling these tools. Bias is no longer only an ethics topic. It is a product risk, a regulatory risk and a sales risk. Buyers ask about it, and so do investors.

The StartupMD
Build Healthcare AI With Clinical Insight
The StartupMD advises healthcare SaaS teams on growth challenges, drawing on expertise in medicine, business and healthcare technology.
Explore healthcare consulting

TL;DR

  • Bias enters healthcare AI through data collection, preparation, validation and historical inequity baked into training data.
  • Documented examples include a mammography tool with more false positives for Black women and a heart failure model that performed worse in younger Black patients.
  • Testing means checking error rates by subgroup, not just reporting one overall accuracy number.
  • Bias monitoring does not end at launch. Models drift as patients, data and care behavior change.
  • U.S. rules, including HHS Section 1557 and FDA draft guidance on AI-enabled devices, already point toward identifying and mitigating bias.

Table of Contents

What AI bias in healthcare models actually means

A model is biased when its errors fall unevenly. It may under-detect disease in one group, over-flag another, or rank patients for care using a proxy that tracks something other than clinical need.

HHS has said that predictive AI and machine learning models in health care may introduce or propagate bias, which can result in discrimination or increased costs depending on how the model was designed, implemented and used. Note the last part. Bias is not only a property of the algorithm. It is a property of the whole deployment.

A review of the evidence describes the consequences plainly: biased medical AI can lead to substandard clinical decisions, misclassification of disease, and the perpetuation of longstanding health-care disparities.

That is the gap a product team has to close before a hospital, health plan or payer will trust the tool.

Where bias comes from

The phrase "bias in, bias out" is a useful shorthand. If the inputs carry a pattern, the model learns it. But the inputs are only one source. The CDC notes that bias can enter through data collection, preparation, validation and historical inequity, often affecting racial and ethnic minority groups and medically underserved populations.

Here is how that looks in practice.

Underrepresentation in training data

A scoping review of sociodemographic bias in clinical machine learning found that underrepresentation of sociodemographic groups in training data was the most frequently suspected mechanism of bias. If a group is thin in the data, the model has less to learn from and performs worse for that group.

Historical inequity in the record

Health records reflect who got care, which tests were ordered and how symptoms were documented. If a group historically received less testing or later treatment, a model trained on those records can read the pattern as the truth about that group's health.

Label and proxy choices

Models need a target to predict. When the target is a stand-in, such as cost as a proxy for need, the model can inherit any inequity in how the proxy is generated. The FTC-referenced playbook tells teams to investigate how label choices influence outcomes for exactly this reason.

Opaque design and weak governance

HHS identifies "black box" algorithms, lack of data governance and poor design as significant contributors to AI-based bias in the U.S. health sector. If nobody can explain how a model reached a result, nobody can check whether the reason was sound.

Metrics that hide the problem

Researchers warn that overreliance on aggregate performance metrics during development can obscure bias and reduce clinical utility for minority subgroups. A model with 92% overall accuracy can still fail a specific group badly.

Real examples of AI bias in healthcare

Founders often ask for a concrete case. Two stand out.

Mammography. A study of a mammography AI software found it was 50% more likely to produce false-positive case scores for Black women than for White women. That could risk inappropriately higher recall rates for Black patients, meaning more callbacks, more anxiety and more follow-up procedures.

Heart failure risk. A 2024 study of a deep learning model for heart failure risk found poorer performance in younger Black patients compared with other patient groups. A tool like that could under-prioritize patients who need attention.

The scoping review cited above also notes that clinical ML algorithms can reproduce or exacerbate bias based on race, sex and gender identity. Race is not the only axis. Age, disability, language and insurance status deserve a look too.

What biased models cost patients and companies

For patients, the harms are clinical. The Lancet Digital Health authors list missed diagnoses, misclassification of disease, incorrect risk prediction and inappropriate recommendations, all of which can worsen health disparities.

For a healthcare SaaS company, the costs are commercial:

  • Procurement friction. Health system buyers increasingly want evidence that a tool works across their population.
  • Regulatory exposure. Covered customers have their own obligations, covered below, and they will pass questions down to vendors.
  • Investor diligence. A fund with a healthcare portfolio wants to know that clinical risk has an owner. A missing answer slows a round.
  • Reputation. One published disparity finding can follow a product for years.

How to test a healthcare AI model for bias

The 2021 playbook referenced by the FTC lays out a four-step framework: Inventory, Screen, Retrain and Prevent. It was written for organizations broadly, but it maps cleanly onto a healthcare product team.

StepWhat you doHealthcare example
InventoryList every algorithm in use and name a stewardA register of risk scores, triage tools and imaging aids, each with an owner
ScreenCompare performance against an ideal target and check error rates by subgroupFalse-positive and false-negative rates by race, sex, age and payer
RetrainFix what the screen found: data, labels or modelAdd data for underrepresented groups, replace a flawed proxy label
PreventSet recurring audits and documentationScheduled reviews, written change logs, escalation paths

The framework suggests designating a steward to maintain the algorithm inventory and running recurring audits so documentation stays rigorous. In a startup, that steward is often nobody by default. Name one.

A practical testing sequence

  1. Define the clinical decision. What does a wrong answer cost, and for whom?
  2. Choose the groups to compare. Include the groups the research flags, plus the groups your customers actually serve.
  3. Report subgroup error rates. Sensitivity, specificity and calibration, not just overall accuracy.
  4. Examine the label. Ask whether the target measures need or something that merely correlates with it.
  5. Test on outside data. A model that works at one site can fail at the next.
  6. Document the results. Keep the methods, the gaps found and the changes made.

Ground truth matters in every step. Measuring output against source records, as in a 433-record accuracy study, shows how a validation design can tie every claim back to evidence, and subgroup bias testing needs that same discipline.

Several of these steps depend on clean, governed data. If yours is not there yet, our 90 to 180 day data governance roadmap is a reasonable place to start. For teams building risk models, our explainer on patient stratification models covers where the stratification logic can go wrong.

How to reduce bias once you find it

Experts recommend collecting diverse datasets, using statistical debiasing methods and ensuring model interpretability as critical steps for clinical AI. Each has limits.

  • Diverse data helps only if the new data is good quality and genuinely represents the target population.
  • Statistical debiasing can trade one error type for another. Clinicians should decide which trade-off is acceptable for the use case.
  • Interpretability lets a clinician spot a result that makes no sense, which a black box does not.

People matter as much as methods. A 2023 review recommends professionally diverse, appropriately trained workforces, governance and transparency practices, and post-deployment monitoring to identify and mitigate bias in clinical algorithms. A data science team alone will miss what a practicing physician sees at once. That is why clinical leadership belongs in model review, not only in the sales deck.

Monitoring does not stop at launch

A model that passes validation can still degrade. HHS notes that even well-designed AI/ML models can become inaccurate or unreliable due to changes in patient characteristics, data over time, health-care behavior, or data capture and management practices.

The FDA makes a related point: retrospective testing and static benchmarks are not designed to predict behavior in dynamic real-world settings, and ongoing systematic performance monitoring is increasingly recognized as relevant to safe and effective use.

In practice, build three things into the product:

  • Dashboards that split performance by subgroup, not just by site.
  • Alerts when input data shifts, such as a new patient mix after a customer acquisition.
  • A clinical review loop where a physician looks at flagged cases and signs off on changes.

U.S. rules that touch healthcare AI bias

Three pieces of guidance matter most for U.S. healthcare SaaS companies. Check the current status of each before you rely on it, because rulemaking and guidance can change.

HHS Section 1557. The final rule applies nondiscrimination protections to patient care decision support tools and requires covered entities to take steps to identify and mitigate discrimination when using them. The HHS FAQ adds that covered providers have an ongoing responsibility to identify their use of tools that directly measure race, color, national origin, sex, age or disability and to make reasonable efforts to mitigate the risk. Your customers carry that duty. Expect them to ask what you can show them.

FDA draft guidance. On January 6, 2025, the FDA issued draft guidance on AI-enabled devices across the total product lifecycle, including strategies to address bias. It also recommends that sponsors describe postmarket performance monitoring and management in marketing submissions. It was a draft when issued, so confirm whether a final version exists.

Whether your tool is a device at all. Many clinical decision support products sit in a gray zone. Our walkthrough of the documents FDA reviewers want for clinical decision support and our regulatory basics for founders help you work out where you stand.

U.S. rules that touch healthcare AI bias — overview diagram

Are there any unbiased AI models?

No model can honestly be called free of bias in every setting. What you can claim is evidence: this model was tested on these populations, performed within these ranges for these subgroups, and is monitored on this schedule.

One perspective article argues that rigorous validation through clinical trials is critical to demonstrate unbiased application before real-world implementation. A fairness claim without subgroup data is marketing. A fairness claim with subgroup data, limits stated and a monitoring plan is a sales asset.

Our perspective: bias is a clinical leadership problem

We work with healthcare SaaS startups, and we see the same pattern. The data science team builds a strong model. The product team ships it. Then a health system's chief medical officer asks, "How does it perform in my patients?" and nobody in the room can answer.

That is the gap a fractional Chief Medical Officer is built to close. A physician leader asks the clinical questions early: Who is missing from this dataset? What does a false negative look like at the bedside? Would I accept this alert for my own family member? Those questions cost little in development and a great deal after a bad deployment.

Our perspective: bias is a clinical leadership problem — overview diagram

We also think founders should resist two extremes. One is treating bias as a compliance checkbox. The other is treating it as an unsolvable problem that excuses inaction. The honest middle is a documented process: inventory, subgroup testing, clinician review and monitoring, owned by a named person.

If something feels misaligned between your model's performance and your clinical story, I would welcome a conversation.

— Paul Bergeron MD, MBA

Getting clinical leadership into your model review

The StartUp MD is a healthcare advisory firm. We provide Fractional Chief Medical Officer and advisory services for healthcare SaaS and digital health companies, including clinical strategy, product evaluation, regulatory guidance and investor support. If you are preparing for a health system pilot, a funding round or a diligence review, we can help you build the clinical evidence and governance story behind your AI.

What this means for founders and investors

For founders:

  • Treat subgroup performance as a release criterion, the same as uptime or security.
  • Name an algorithm steward and keep an inventory.
  • Write the validation and monitoring plan down. Buyers and regulators will ask for it.
  • Bring a clinician into model review early. Our guide on what a CMO does in a healthcare startup explains the role.

For investors with healthcare portfolio companies:

  • Ask for subgroup results, not a single accuracy figure.
  • Ask who owns post-deployment monitoring.
  • Ask how the company would learn that performance had degraded.
  • Check that the product's clinical claims match its validation population.

Founders building the broader pitch may also find our investor pitch checklist useful as a way to place this evidence in the story.

FAQ

Can you provide an example of AI bias in healthcare?

Yes. A study of a mammography AI software found it was 50% more likely to produce false-positive case scores for Black women than for White women. That could lead to higher recall rates for Black patients. A 2024 study of a heart failure risk model also found poorer performance in younger Black patients.

How does bias get into healthcare AI?

It enters through data collection, preparation, validation and historical inequity in training data. Underrepresentation of certain groups is the most frequently suspected mechanism in one scoping review. Opaque design and weak data governance add to the risk.

How do you test a healthcare AI model for bias?

Start with an inventory of your algorithms, then check error rates across patient subgroups and examine how the model's label was chosen. Retrain where you find gaps, and set recurring audits to prevent drift. Overall accuracy alone can hide a problem in one group.

Are there any unbiased AI models?

Not in any way you can guarantee for every population and setting. The defensible position is documented evidence of performance across subgroups, with limits stated and monitoring in place after launch.

Does the law require bias testing for healthcare AI?

The HHS Section 1557 final rule requires covered entities to take steps to identify and mitigate discrimination when using patient care decision support tools. FDA draft guidance from January 2025 recommends bias strategies and postmarket monitoring for AI-enabled devices. Confirm current status with counsel and the agencies, since guidance can change.

Sources